Site activation, the process of getting a clinical trial site from selection through first patient enrolled, remains one of the most variable and least predictable phases of trial execution, and sponsors frequently lack a clear internal benchmark for what a reasonable timeline should look like for their specific trial type.
Industry-wide averages are of limited use on their own because activation timelines vary enormously by therapeutic area, trial complexity, and country. A straightforward Phase 2 study in a common condition at an experienced site network activates on a very different timeline than a first-in-human oncology trial requiring specialized infrastructure at a smaller number of academic centers.
Contract execution and budget negotiation remain, in most sponsor organizations, the single largest source of activation delay, frequently exceeding the time required for institutional review board approval or regulatory submission. Standardizing contract templates and pre-negotiating budget ranges before site selection begins can meaningfully compress this phase.
Site experience with the specific sponsor or CRO matters more than raw site experience in general. A site with an established working relationship and familiar systems for a given sponsor typically activates faster than an equally experienced site encountering that sponsor’s processes for the first time, which is a useful factor to weight during site selection.
Tracking activation timelines by phase, contract execution, IRB approval, and site readiness training, rather than as a single undifferentiated number, allows a sponsor to identify which specific stage is actually driving delays in their program, since the bottleneck varies considerably from one trial to the next.
Clinical Trial Ops Brief analysis that breaks activation timelines down by these individual phases and compares them across trial types, the kind regularly published by The Clinical Trial Vanguard, gives operations teams a more actionable benchmark than a single industry average ever could.
